Small leucine-rich proteoglycans in atherosclerotic lesions: Novel targets of chronic statin treatment?

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 232-243

  Marzoll, Andrea ^a   Melchior Becker, Ariane ^b   Cipollone, Francesco ^c   Fischer, Jens W ^b  

^a Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerotic plaque stability; Biglycan; Decorin; Remodelling; Statins

Indexed keywords

APOLIPOPROTEIN E; BIGLYCAN; COLLAGEN; DECORIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SCLEROPROTEIN; SULFONAMIDE;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CAROTID ENDARTERECTOMY; CELL LINE; CHEMISTRY; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; MOUSE MUTANT;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIGLYCAN; CELL LINE; COLLAGEN; DECORIN; ENDARTERECTOMY, CAROTID; EXTRACELLULAR MATRIX PROTEINS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUCINE; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PROTEOGLYCANS; PYRIMIDINES; SULFONAMIDES;

MUS;

EID: 79951930958     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00986.x     Document Type: Article

References (41)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-9.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
3. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000; 101: 207-13.
4. Ridker PM, Rifai N, Pfeffer MA, et al Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100: 230-5.
5. Sparrow CP, Burton CA, Hernandez M, et al Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001; 21: 115-21.
6. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002; 20: 303-28.
7. *3-leiden transgenic mice. Evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003; 108: 1368-74.
8. Crouse JR, 3rd, Grobbee DE, O'Leary DH, et al Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis-the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther. 2004; 18: 231-8.
9. -/- mice in vivo. Circulation. 2003; 107: 2480-6.
10. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007; 27: 15-26.
11. Libby P, Sasiela W. Plaque stabilization: Can we turn theory into evidence? Am J Cardiol. 2006; 98: 26-33.
12. Newby AC, Zaltsman AB. Fibrous cap formation or destruction-the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res. 1999; 41: 345-60.
13. Shah PK, Falk E, Badimon JJ, et al Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995; 92: 1565-9.
14. Fukumoto Y, Libby P, Rabkin E, et al Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipi-demic rabbits. Circulation. 2001; 103: 993-9.
15. Iozzo RV. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol. 1997; 32: 141-74.
16. Ameye L, Young MF. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology. 2002; 12: 107-16.
17. Danielson KG, Baribault H, Holmes DF, et al Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997; 136: 729-43.
18. Xu T, Bianco P, Fisher LW, et al Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet. 1998; 20: 78-82.
19. Meyers CD, Tannock LR, Wight TN, et al Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res. 2003; 44: 2152-60.
20. Dai G, Freudenberger T, Zipper P, et al Chronic ultraviolet B irradiation causes loss of hyaluronic Acid from mouse dermis because of down-regulation of hyaluronic Acid synthases. Am J Pathol. 2007; 171: 1451-61.
21. Huang F, Thompson JC, Wilson PG, et al Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res. 2008; 49: 521-30.
22. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995; 9: 974-80.
23. Burke AP, Kolodgie FD, Farb A, et al Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001; 103: 934-40.
24. Kinsella MG, Fischer JW, Mason DP, et al Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem. 2000; 275: 13924-32.
25. Vernon RB, Gooden MD. An improved method for the collagen gel contraction assay. In Vitro Cell Dev Biol Anim. 2002; 38: 97-101.
26. Glossl J, Beck M, Kresse H. Biosynthesis of proteodermatan sulfate in cultured human fibroblasts. J Biol Chem. 1984; 259: 14144-50.
27. Schartl M, Bocksch W, Koschyk DH, et al Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001; 104: 387-92.
28. Crisby M, Nordin-Fredriksson G, Shah PK, et al Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001; 103: 926-33.
29. Underhill HR, Yarnykh VL, Hatsukami TS, et al Carotid plaque morphology and composition: initial comparison between 1.5- and 3.0-T magnetic field strengths. Radiology. 2008; 248: 550-60.
30. Imai K, Hiramatsu A, Fukushima D, et al Degradation of decorin by matrix metallo-proteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 1997; 322: 809-14.
31. Monfort J, Tardif G, Reboul P, et al Degradation of small leucine-rich repeat proteoglycans by matrix metallo-protease-13: identification of a new bigly-can cleavage site. Arthritis Res Ther. 2006; 8: R26.
32. Riessen R, Isner JM, Blessing E, et al Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol. 1994; 144: 962-74.
33. Weis SM, Zimmerman SD, Shah M, et al A role for decorin in the remodeling of myocardial infarction. Matrix Biol. 2005; 24: 313-24.
34. Corsi A, Xu T, Chen XD, et al Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are syner-gized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res. 2002; 17: 1180-9.
35. Fischer JW, Kinsella MG, Clowes MM, et al Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats. Circ Res. 2000; 86: 676-83.
36. Jarvelainen H, Vernon RB, Gooden MD, et al Overexpression of decorin by rat arterial smooth muscle cells enhances contraction of type I collagen in vitro. Arterioscler Thromb Vasc Biol. 2004; 24: 67-72.
37. Heegaard AM, Corsi A, Danielsen CC, et al Biglycan deficiency causes spontaneous aortic dissection and rupture in mice. Circulation. 2007; 115: 2731-8.
38. Geng Y, McQuillan D, Roughley PJ. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol. 2006; 25: 484-91.
39. Skalen K, Gustafsson M, Rydberg EK, et al Subendothelial retention of athero-genic lipoproteins in early atherosclerosis. Nature. 2002; 417: 750-4.
40. Nakashima Y, Fujii H, Sumiyoshi S, et al Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007; 27: 1159-65.
41. Little PJ, Osman N, O'Brien KD. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol. 2008; 19: 448-54.